ACTA Otorhinolaryngologica Italica https://old.actaitalica.it/ <h3 style="text-align: center;"> </h3> <h3 style="text-align: center;"> </h3> <h3 style="text-align: center;"> </h3> <p> </p> <div class="alert alert-danger" role="alert"> <h3 style="text-align: center;">We are making updates to improve our service. Currently, you cannot submit new submissions or register with the site. We apologize for the inconvenience and thank you for your understanding</h3> </div> <p> </p> <p> </p> en-US <h2><strong>AUTHORSHIP STATEMENT FORM</strong></h2> <p><strong>The corresponding author must sign the </strong><strong>Authorship Statement Form</strong><strong>, save it in .pdf and return it </strong><strong>by uploading at our online submission platform http://www.actaitalica.it/. </strong></p> <p><strong>It is the policy of the Journal to correspond exclusively with one designated corresponding author. As the corresponding author, it is your responsibility to communicate with your co-authors.</strong></p> <p><strong>AUTHORSHIP RESPONSIBILITY</strong></p> <p>(1) All authors participated sufficiently in the intellectual content, analysis of data (if applicable) and writing of the article, as defined by the criteria for authorship by the International Committee of Medical Journal Editors (http://www.icmje.org/). (2)&nbsp;The corresponding author certifies that the definitive version of the manuscript has been approved by all co-authors, as well as, by the director of the Institute or Department where the work has been carried out. (3) All persons who have made substantial contributions to the work reported in this manuscript (e.g., data collection, writing or editing assistance) but who do not fulfill the authorship criteria are named along with their specific contributions as an acknowledgement in the manuscript. The corresponding author certifies that all persons named in the acknowledgement section have provided written permission to be named. (4) All authors have reviewed the final version of the article and approve it for publication. (5) Authors must state that the article submitted has not been previously published, and is not under consideration or accepted for publication (in whole or in part) elsewhere nor have the authors assigned any right or interest in the article to any third party. (6) Written permission from the authors to reproduce any material with copyright elsewhere has been obtained prior to submission. (7) Authors must specify that consent has been obtained from patients taking part in the investigations or, in the case of paediatric patients, from the guardian/s and that they have obtained written releases from patients whose names or photographs are submitted as part of the article. (8) For reports containing original data, the corresponding author should have full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of data analysis. (9) Any manuscript concerned with human subjects, medical records, or human tissue that is submitted to “Acta Otorhinolaryngologica Italica” should comply with the principles stated in the Declaration of Helsinki “Ethical Principles for Medical Research Involving ‘Human Subjects”, adopted by the 18<sup>th</sup> World Medical Assembly, Helsinki, Finland, June 1964, and as amended most recently by the 64<sup>th</sup> World Medical Assembly, Fontaleza, Brazil, October 2013. If the study involves human or animal subjects or records of human patients ethical approval MUST have been obtained. The corresponding author must state whether ethical approval was given, by whom and the relevant Judgement’s reference number. The manuscript should contain a statement that the work has been approved by the appropriate Ethical Committee related to the institution(s) in which the work was performed, and that subjects gave informed consent to the work. “Acta Otorhinolaryngologica Italica” requires institutional Ethics Committee approval for all human studies. For retrospective studies on patients’ records either a statement of approval or a statement of exemption from the Committee is required. <strong>Ref N° of the Ethical Committee Approval must be indicated in the Authorship Statement Form. The study was approved by the Institutional Ethical Committee (the Name of the Institution must be indicated in the Authorship Statement Form) and this is clearly stated in the Methods section of the article.&nbsp;</strong>This statement should also be provided upon submission of the manuscript. Studies involving experiments with animals must state that their care was in accordance with institution guidelines and relevant national laws. (10) The article contains no libelous or unlawful statements, does not infringe the privacy of others, or contains material or instructions that might cause harm or injury. The corresponding author shall indemnify and hold the Editors and its agents and licensees harmless from any damages, costs, and expenses (including reasonable attorney’s fees and costs of settlement) resulting by reason of any claim, action, or proceeding finally sustained or settled inconsistent with the foregoing warranties and representations. (11) All manuscripts are screened for plagiarism, which implies immediate rejection. Suspected plagiarism is handled in accordance with the COPE flowcharts (http://publicationethics.org/resources/flowcharts).</p> <p>Every author or co-author of any article published in this Journal is solely responsible for the contents of the article, for the statement made in their paper and for the material sent. Every author or co-author needs to fully comply with the Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Data Protection Regulation): «<em>Article 9. Processing of personal data revealing racial or ethnic origin, political opinions, religious or philosophical beliefs, or trade union membership, and the processing of genetic data, biometric data for the purpose of uniquely identifying a natural person, data concerning health or data concerning a natural person's sex life or sexual orientation shall be prohibited».</em></p> <p><strong>PRINTING CONTRIBUTION.</strong> The corresponding author accept to be charged Euro 300.00 as printing contribution for the article (for articles submitted from March 1, 2021). Payment details will be sent with galley proofs.</p> <p><strong>PRIVACY POLICY STATEMENT. </strong>Personal data of the author will be managed by the Publisher in full compliance with the current legislation on the privacy protection (art.&nbsp;13 of EU regulation 2016/6799). According to articles 15-20 of the GDPR, any author may&nbsp;exercise specific rights, including the right to obtain access to personal data in an intelligible form, correct, update or cancel them.&nbsp;Authors will also have the right to obtain from the Publisher limitation of data processing, and may also oppose to data processing legitimate reasons.&nbsp;In the case that the author believes that processing of his/her own personal data infringes the of GDPR regulation, he/she has the right to make a complaint&nbsp;to the Supervisory Authority for the Protection of Personal Data according to art.&nbsp;77 of the GDPR. Controller of data processing, according to art.&nbsp;4.1.7 of the GDPR, is Mrs. Donatella Paoletti for Pacini Editore Srl, with registered office in 56121 Pisa, Italy, Via A Gherardesca n.&nbsp;1. To exercise the rights of GDPR referred to in paragraph 6 of the same article, you can address any request for information to the following e-mail:&nbsp;privacy@pacinieditore.it. For further information refer to the website:&nbsp;https://www.actaitalica.it/about/privacy</p> <p><strong>FINANCIAL DISCLOSURE. </strong>All authors must state any information that may be perceived as potential <em>conflict of interest</em>. All authors must disclose all their affiliations including any relevant personal or institutional financial involvement (employment by an industrial concern, consultancies, honoraria, speakers bureau, stock ownership or options, expert testimony, grants received or pending, membership on a standing advisory council or committee, a seat on the board of directors, or being publicly associated with a company or its products, royalties, donation of medical equipment, etc.) with any organization that to any author’s knowledge has a direct interest, particularly a financial interest, in the subject matter or materials discussed. This declaration will be treated by the Editor as confidential while the paper is under review, and will not be made known to Reviewers. &nbsp;Please indicate on the <strong>Authorship Statement Form</strong> whether or not you have or may have such a conflict of interest regarding the content of this article and is the nature of it.</p> <p><strong>COPYRIGHT TRANSFER AGREEMENT. </strong>(a) Authors assign to “Acta Otorhinolaryngologica Italica”, all copyright in and to the article, including but not limited to the right to publish, republish, transmit, sell, distribute and otherwise use the article in whole or in part, in electronic and print editions of the Journal and in derivative works throughout the world, in all languages and in all media of expression now known or later developed, and to license or permit others to do so. (b) The authors retain all proprietary rights, other than copyright, such as patent rights. The authors retain the right to reuse any portion of the work, without charge, in personal compilations or other publications consisting solely of the author(s’) own works, including the author(s’) personal web home page, and to make copies of all or part of the Work for the author(s’) use for lecture or classroom purposes. The corresponding author declares that any person named as co-author of the article is aware of the submission and has agreed to being so named. The corresponding author accepts responsibility for releasing this material on behalf of any and all co-authors. The corresponding author declares that statements and opinions given in the article are the expression of the authors. Responsibility for the content of the article rests upon the authors.</p> <p><strong>&nbsp;</strong></p> cesare.piazza@unibs.it (Cesare Piazza) support-actaorl@pacinieditore.it (Manuela Mori, Valentina Barberi) Mon, 30 Sep 2024 13:27:56 +0000 OJS 3.1.2.4 http://blogs.law.harvard.edu/tech/rss 60 Endoscopic transnasal approach to remove an intraorbital bullet: systematic review and case report https://old.actaitalica.it/article/view/2868 <p><strong>Introduction</strong>. Intraorbital foreign bodies (IOFBs) represent a clinical challenge: surgical management can be controversial and different strategies have been proposed. When removal is recommended, depending on the location and nature of the IOFB both external and endoscopic approaches have been proposed, with significantly different surgical corridors to the orbit and different morbidities. <br><strong>Methods</strong>. We performed a literature review of cases of IOFBs that received exclusive endoscopic transnasal surgical treatment to evaluate the role of this surgery in these occurrences. We also present a case of an intraorbital intraconal bullet that was successfully removed using an endoscopic transnasal approach with good outcomes in terms of ocular motility and visual acuity. <br><strong>Results</strong>. A limited number of cases of IOFBs have been treated with an exclusive endoscopic transnasal approach. When in the medial compartment, this approach appears to be safe and effective. In our case, two months after surgery the patient showed complete recovery with no significant long-term sequelae.<br><strong>Conclusions</strong>. When feasible, an endoscopic transnasal approach for intraorbital foreign bodies represents a valid surgical technique with optimal outcomes&nbsp;and satisfactory recovery.</p> Giacomo Sollini, Alessia Giorli, Matteo Zoli, Paolo Farneti, Giorgio Arena, Fabio Astarita, Diego Mazzatenta, Ernesto Pasquini Copyright (c) 2024 Società Italiana di Otorinolaringoiatria e chirurgia cervico facciale http://creativecommons.org/licenses/by-nc-nd/4.0 https://old.actaitalica.it/article/view/2868 Thu, 02 May 2024 00:00:00 +0000 Management and prognosis of iatrogenic perforations of the cervical oesophagus and hypopharynx https://old.actaitalica.it/article/view/2905 <p><strong>Objective</strong>. The study aimed to identify factors affecting the management and prognosis of iatrogenic cervical oesophageal and hypopharyngeal perforations (iCEHPs). <br><strong>Methods</strong>. We retrospectively analysed 24 patients treated for iCEHP between 2004 and 2021 at a tertiary university medical centre. Data on demographics, clinical features, imaging, management and outcomes were collected. Factors associated with primary management and patient outcome were assessed. <br><strong>Results</strong>. The most common management approach was surgical neck exploration (15 patients, 62.5%). Surgical management was used in 93% of uncontained perforations compared to 11% of contained perforations (p &lt; 0.001). Surgically-treated patients had higher levels of C-reactive protein (CRP) than conservatively-treated patients (median, 18.3 <em>vs</em> 4.8 mg/dL; p = 0.001). Delayed diagnosis (≥ 24 hours) was associated with increased mortality (100 <em>vs</em> 5%; p = 0.011). The mortality rate was significantly higher in patients who had a history of neck irradiation than in patients who did not (67 <em>vs</em> 5%; p = 0.032). <br><strong>Conclusions</strong>. Early diagnosis of iCEHP improves outcomes. The appropriate management should be carefully selected on the basis of CRP level and imaging findings. Prior neck radiation is a poor prognostic factor.</p> Einav G. Levin, Amit Ritter, Amir Amitai, Thomas Shpitzer, Gideon Bachar, Aviram Mizrachi, Yaniv Hamzany Copyright (c) 2024 Società Italiana di Otorinolaringoiatria e chirurgia cervico facciale http://creativecommons.org/licenses/by-nc-nd/4.0 https://old.actaitalica.it/article/view/2905 Mon, 30 Sep 2024 11:53:09 +0000 Squamous cell carcinoma metastatic to the lymph nodes of the parapharyngeal space: case series and systematic review https://old.actaitalica.it/article/view/2993 <p><strong>Objective</strong>. Parapharyngeal space (PPS) is a rare and unusual site of head and neck squamous cell carcinoma (SCC) metastases. Treatment strategy for PPS metastases is still not well defined. This research aims to investigate the clinical implications and oncological outcomes of SCC metastases in PPS. <br><strong>Material and methods</strong>. A systematic review was conducted according to PRISMA criteria. The authors considered only articles reporting the history and treatment of patients with PPS SCC metastases. A retrospective chart review was conducted in two tertiary referral academic centers collecting data of patients with diagnosis of PPS SCC metastases between 2010 and 2023 to study their outcome based on clinical presentation and treatment strategy. <br><strong>Results</strong>. The retrospective chart review showed that the oropharynx was the most frequent primary tumour site. The advanced stage at the time of diagnosis was related to poorer survival and higher recurrence rates. A significant difference in 2-year overall survival in the subgroup of patients who experienced PPS metastases within the primary treatment and those who experienced PPS metastases as regional recurrence (66.7 <em>vs</em> 30.8%) was observed. Similar low survival rates were reported in the literature review with a mean overall and disease-free survival of 19.8 and 8.6 months, respectively. <br><strong>Conclusions</strong>. PPS metastases are associated with a dismal prognosis, especially when diagnosed as regional recurrence after primary treatment, due to patients’ poor general conditions and difficulty of treatment.</p> Matteo Fermi, Cecilia Botti, Francesco Chiari, Andi Abeshi, Livio Presutti, Matteo Miglio, Francesco Mattioli, Daria Maria Filippini, Sara Valerini, Daniele Marchioni, Gabriele Molteni, Edoardo Serafini Copyright (c) 2024 Società Italiana di Otorinolaringoiatria e chirurgia cervico facciale http://creativecommons.org/licenses/by-nc-nd/4.0 https://old.actaitalica.it/article/view/2993 Mon, 30 Sep 2024 12:05:31 +0000 Recurrent respiratory papillomatosis: comparing in-office and operating room treatments https://old.actaitalica.it/article/view/2951 <p style="font-weight: 400;"><strong>Objective</strong>. We report the management of recurrent respiratory papillomatosis (RRP) employing a protocol that includes both office-based (OB) and general anaesthesia (GA) procedures. Quality of life (QoL) outcomes in the OB cohort were compared to those obtained from an historical cohort treated only under GA. <br><strong>Methods</strong>. Patients affected by RRP from 2019 until 2023 (“new protocol”) and from 2012 to 2019 (“historical protocol”) were enrolled. In both groups the Derkay site score (DSS) was calculated. In patients adhering to the new protocol, questionnaires measuring QoL were prospectively administered (voice handicap hindex-10 [VHI-10] along with a specific questionnaire to measure the tolerance to the OB procedures). A cost analysis was also performed. <br><strong>Results</strong>. In all, 35 patients composed the new protocol cohort and 13 the historical. In the first group, patients underwent a median of 4 treatments. At 2 years, 68% of patients were treated ex-clusively in the office. Overall, for the new protocol, median DSS and VHI-10 after one year were both significantly lower than those at baseline [2 <em>vs</em> 4 and 3 <em>vs</em> 14, respectively; p &lt; 0.001]. No differences were found between the new and the historical protocol cohorts considering DSS over time. <br><strong>Conclusions</strong>. Treatment of RRP may be conducted successfully in an office-based setting reducing healthcare costs.</p> Marta Filauro, Alberto Vallin, Claudio Sampieri, Pietro Benzi, Giulia Gabella, Marta De Vecchi, Alessandro Ioppi, Francesco Mora, Giorgio Peretti Copyright (c) 2024 Società Italiana di Otorinolaringoiatria e chirurgia cervico facciale http://creativecommons.org/licenses/by-nc-nd/4.0 https://old.actaitalica.it/article/view/2951 Mon, 30 Sep 2024 00:00:00 +0000 TIM-3-driven macrophage polarisation is associated to recalcitrant chronic rhinosinusitis with nasal polyps https://old.actaitalica.it/article/view/2717 <p><strong>Objective</strong>. This study evaluated the expression of TIM-3 and its influence on macrophage polarisation in recalcitrant chronic rhinosinusitis with nasal polyps (CRSwNP). <br><strong>Methods</strong>. We detected TIM-3 expression in serum and tissue samples of healthy controls (HC), primary CRSwNP, and patients with recurrent CRSwNP. Macrophage markers were detected among three groups, and their correlations with TIM-3 levels were examined. Macrophages from circulating blood were collected and used to examine the impact of TIM-3 on polarisation in vitro. <br><strong>Results</strong>. TIM-3 levels were enhanced in the CRSwNP group compared to the HC group. Tissue immunofluorescence revealed elevated TIM-3 expression in patients with CRSwNP, and patients with multiple recurrences exhibited higher TIM-3 levels compared to their first recurrence and baseline levels. Tissue CD163 and CD206 levels were higher in recurrent CRSwNP in comparison with primary cases and HCs, and had a positive correlation with TIM-3 levels. TIM-3 overexpression promoted M2 polarisation and enhanced TGF-β1 and IL-10 secretion. <br><strong>Conclusions</strong>. TIM-3 expression was enhanced in patients with CRSwNP, especially in those undergoing revision surgeries. TIM-3 may be a novel biomarker for recalcitrant CRSwNP. TIM-3-driven M2 polarisation might be involved in the mechanisms of recurrent CRSwNP.</p> Tao Jiang, Tao Yu, Lu Jiang, Zongjing Tong Copyright (c) 2024 Società Italiana di Otorinolaringoiatria e chirurgia cervico facciale http://creativecommons.org/licenses/by-nc-nd/4.0 https://old.actaitalica.it/article/view/2717 Mon, 30 Sep 2024 12:44:09 +0000 Management of frontal sinus and frontal recess inverted papilloma: our experience and systematic review https://old.actaitalica.it/article/view/2331 <p><strong>Objective</strong>. For frontal sinus inverted papilloma (FSIP) management, an endoscopic endonasal approach (EEA) can be combined (or not) with an external approach by an osteoplastic flap (OPF) or with a more conservative open approach. The present study aims to describe our experience in the management of FSIP, focusing on disease-related and anatomical features influencing outcomes and recurrence.<br><strong>Methods</strong>. This case series of FSIP investigated anatomical and disease-related predictors of recurrence associated with EEA or a combined EEA-OPF approach. A systematic review was also performed, selecting publications on IP with the insertion point in the frontal sinus or frontal recess. <br><strong>Results</strong>. Among 30 patients included, 18 underwent EEA, while 12 received a combined EEA-OPF approach. During a median follow-up of 37 months, the frontal sinus was cleared of IP in all cases except 2 in the EEA group, who presented a complex posterior wall shape of the frontal sinus. From the systematic review, a combined EEA-OPF approach was associated with a lower risk of recurrence. <br><strong>Conclusions</strong>. A correct indication for a combined EEA-OPF approach is paramount and should integrate all disease-related and anatomical features, including posterior wall shape.</p> Piergiorgio Gaudioso, Alessandro Vinciguerra Copyright (c) 2024 Società Italiana di Otorinolaringoiatria e chirurgia cervico facciale http://creativecommons.org/licenses/by-nc-nd/4.0 https://old.actaitalica.it/article/view/2331 Mon, 30 Sep 2024 12:52:12 +0000 Predicting excellent response to radioiodine in differentiated thyroid cancer using machine learning https://old.actaitalica.it/article/view/3029 <p><strong>Objective</strong>. If excellent response (ER) occurs after radioactive iodine (RAI) treatment in patients with differentiated thyroid carcinoma (DTC), the recurrence rate is low. Our study aims to predict ER at 6-24 months after RAI by using machine learning (ML) methods in which clinicopathological parameters are included in patients with DTC without distant metastasis. <br><strong>Methods</strong>. Treatment response of 151 patients with DTC without distant metastasis and who received RAI treatment was determined (ER/nonER). Thyroidectomy ± neck dissection pathology data, laboratory, and imaging findings before and after RAI treatment were introduced to ML models. <br><strong>Results</strong>. After RAI treatment, 118 patients had ER and 33 had nonER. Before RAI treatment, TgAb was positive in 29% of patients with ER and 55% of patients with nonER (p = 0.007). Eight of the ML models predicted ER with high area under the ROC curve (AUC) values (&gt; 0.700). The model with the highest AUC value was extreme gradient boosting (AUC = 0.871), the highest accuracy shown by gradient boosting (81%). <br><strong>Conclusions</strong>. ML models may be used to predict ER in patients with DTC without distant metastasis.</p> Ogün Bülbül, Demet Nak Copyright (c) 2024 Società Italiana di Otorinolaringoiatria e chirurgia cervico facciale http://creativecommons.org/licenses/by-nc-nd/4.0 https://old.actaitalica.it/article/view/3029 Mon, 30 Sep 2024 13:00:04 +0000 Relationships of the vidian nerve and internal carotid artery: MRI and intraoperative surgical evaluation https://old.actaitalica.it/article/view/2889 <p><strong>Objective</strong>. Skull base anatomy around the internal carotid artery (ICA) is extremely complex. Among anatomical landmarks studied, the vidian canal has been thoroughly evaluated, unlike the vidian nerve (VN). Our aim is to evaluate the VN-ICA relationships, and understand their role in terms of surgical planning. <br><strong>Methods</strong>. Fifty MRI examinations of 100 healthy petro-spheno-clival regions were reviewed in order to evaluate the relationship between the vidian nerve axis (VNA) and the petrous ICA. Twentyseven cases of expanded endonasal approaches to petrous apex region were evaluated to check the VN-ICA relationship intraoperatively.<br><strong>Results</strong>. MRI evaluations showed that, in 23% of cases, the VNA was below the edge of the ICA, in 45% it was at the edge of the ICA and in 32% it ended up above the edge of the ICA. Surgically speaking, in 9 of 28 petrous apex approaches, the VN ended above the inferior edge of the petrous carotid. <br><strong>Conclusions</strong>. MRI evaluation adds useful information in planning the surgical approach to petro-spheno-clival regions, even if the identification of VNA, in these cases, may not be radiologically possible. Surgical experience confirms the importance of VN identification in guiding the surgeon in complex cases, and also outline the possible risks of relying only on this landmark.</p> Iacopo Dallan, Marco Verstegen, Silvia Canovetti, Mario Turri-Zanoni, Christos Georgalas, Giacomo Fiacchini, Christina Cambi, Daniel Prevedello, Wouter van Furth Copyright (c) 2024 Società Italiana di Otorinolaringoiatria e chirurgia cervico facciale http://creativecommons.org/licenses/by-nc-nd/4.0 https://old.actaitalica.it/article/view/2889 Mon, 30 Sep 2024 13:09:44 +0000 A case of otoliquorrhoea secondary to immunotherapy response in head and neck cutaneous squamous cell carcinoma. When abrupt response may worry the physician https://old.actaitalica.it/article/view/2647 Luigi Lorini, Michele Tomasoni, Paolo Rondi, Andrea Esposito, Marco Ravanelli, Alberto Schreiber, Antonio Biroli, Paolo Bossi Copyright (c) 2023 Società Italiana di Otorinolaringoiatria e chirurgia cervico facciale http://creativecommons.org/licenses/by-nc-nd/4.0 https://old.actaitalica.it/article/view/2647 Tue, 10 Oct 2023 00:00:00 +0000